Goa-based Molbio Diagnostics has set its IPO price band at Rs 768-807 per share, aiming to raise Rs 940 crore. The offer opens on August 10 and closes on August 12, 2026. Investors should weigh the company's strong revenue growth against its increased debt levels and reliance on government-led health programs.
Molbio Diagnostics, a molecular diagnostics firm headquartered in Goa, has announced the details for its upcoming initial public offering (IPO). The company has fixed its price band at Rs 768 to Rs 807 per equity share. The IPO will open for public subscription on August 10 and conclude on August 12, 2026. At the upper end of the price band, the company is valued at approximately Rs 9,300 crore.
The offering aims to raise a total of Rs 939.7 crore. This includes a fresh issue of shares worth Rs 200 crore and an offer-for-sale (OFS) of 91.66 lakh shares valued at Rs 739.7 crore. Through the OFS, existing investors, including Motilal Oswal's India Business Excellence Fund and V-Sciences Investments (a subsidiary of Singapore's Temasek Holdings), along with promoters, will be selling part of their stake. The shares are tentatively scheduled to list on the BSE and NSE on August 17, 2026.
Financial Growth and Business Risks
Molbio Diagnostics operates the Truenat platform, a patented system used for rapid, decentralized PCR testing for various diseases, including tuberculosis and COVID-19. In the recent fiscal year (FY26), the company reported revenue of Rs 1,445.7 crore, marking a 41.7% increase compared to the previous year. During the same period, its net profit stood at Rs 166.6 crore, a growth of 14.8%. While the revenue growth is notable, the profit growth has been slower in comparison, a trend investors often analyze to understand operational efficiency.
A key aspect for investors to track is the company's financial structure and business model. The company’s debt levels have tripled in the recent fiscal period, which may affect its financial flexibility. Furthermore, a significant portion of Molbio’s business depends on government-led health programs. Changes in government policy, funding for public health initiatives, or procurement cycles could directly impact the company's revenue stability.
Use of Funds and Logistics
The Rs 200 crore raised from the fresh issue is planned for capital spending. The company intends to use Rs 105.5 crore to build a new research and development facility and a Center of Excellence. Another Rs 72.2 crore is designated for purchasing plant and machinery for its manufacturing units in Goa and Visakhapatnam. The remaining funds are allocated for general corporate purposes.
For retail investors, the minimum bid size is 18 equity shares, requiring a minimum investment of Rs 14,526. Employees of the company have been allocated shares worth Rs 1.5 crore and will receive a discount of Rs 76 per share compared to the final offer price. As the company moves toward its listing, the progress of its manufacturing expansion and its ability to manage debt while sustaining growth will be important monitorables for the market.